PL2766040T3 - Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi - Google Patents
Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersiInfo
- Publication number
- PL2766040T3 PL2766040T3 PL12778010T PL12778010T PL2766040T3 PL 2766040 T3 PL2766040 T3 PL 2766040T3 PL 12778010 T PL12778010 T PL 12778010T PL 12778010 T PL12778010 T PL 12778010T PL 2766040 T3 PL2766040 T3 PL 2766040T3
- Authority
- PL
- Poland
- Prior art keywords
- pertuzumab
- trastuzumab
- docetaxel
- carboplatin
- early
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
- 190000008236 carboplatin Chemical compound 0.000 title 1
- 229960004562 carboplatin Drugs 0.000 title 1
- 229960003668 docetaxel Drugs 0.000 title 1
- 229960002087 pertuzumab Drugs 0.000 title 1
- 229960000575 trastuzumab Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Packages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547535P | 2011-10-14 | 2011-10-14 | |
| US201161567015P | 2011-12-05 | 2011-12-05 | |
| US201261657669P | 2012-06-08 | 2012-06-08 | |
| US201261682037P | 2012-08-10 | 2012-08-10 | |
| US201261694584P | 2012-08-29 | 2012-08-29 | |
| PCT/US2012/059683 WO2013055874A2 (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| EP12778010.4A EP2766040B1 (en) | 2011-10-14 | 2012-10-11 | Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2766040T3 true PL2766040T3 (pl) | 2019-11-29 |
Family
ID=47073543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12778010T PL2766040T3 (pl) | 2011-10-14 | 2012-10-11 | Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi |
Country Status (29)
| Country | Link |
|---|---|
| US (9) | US20130095172A1 (pl) |
| EP (5) | EP2766040B1 (pl) |
| JP (8) | JP2014530235A (pl) |
| KR (4) | KR20230028585A (pl) |
| CN (8) | CN116271013A (pl) |
| AU (4) | AU2012322797B2 (pl) |
| BR (1) | BR112014007521A8 (pl) |
| CL (1) | CL2014000889A1 (pl) |
| DK (1) | DK2766040T3 (pl) |
| EA (1) | EA034390B1 (pl) |
| ES (1) | ES2736005T3 (pl) |
| HK (1) | HK1202242A1 (pl) |
| HR (1) | HRP20191247T1 (pl) |
| HU (1) | HUE044352T2 (pl) |
| IL (4) | IL301603A (pl) |
| IN (1) | IN2014CN02703A (pl) |
| LT (1) | LT2766040T (pl) |
| MX (2) | MX2014004021A (pl) |
| MY (2) | MY172326A (pl) |
| PE (1) | PE20142363A1 (pl) |
| PH (1) | PH12019500519A1 (pl) |
| PL (1) | PL2766040T3 (pl) |
| PT (1) | PT2766040T (pl) |
| RS (1) | RS58944B1 (pl) |
| SG (3) | SG11201401432XA (pl) |
| SI (1) | SI2766040T1 (pl) |
| UA (2) | UA123092C2 (pl) |
| WO (1) | WO2013055874A2 (pl) |
| ZA (1) | ZA201401259B (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
| EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
| DK3108886T3 (da) | 2010-04-21 | 2020-08-10 | Syntarga Bv | Konjugater af CC-1065-analoger og bifunktionelle linkere |
| US20130095172A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| CA3071678A1 (en) | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
| EP3010501B1 (en) * | 2013-06-19 | 2021-11-03 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| BR112016013896A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2 |
| CN104726462A (zh) * | 2013-12-20 | 2015-06-24 | 北京天广实生物技术股份有限公司 | 抗her2人源化抗体mil41、其制备方法及用途 |
| EP3069735B1 (en) * | 2014-01-10 | 2018-03-14 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in the treatment of bladder cancer |
| EP3092010B1 (en) | 2014-01-10 | 2018-07-11 | Synthon Biopharmaceuticals B.V. | Method for purifying cys-linked antibody-drug conjugates |
| KR20160099725A (ko) * | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
| WO2016094341A1 (en) * | 2014-12-08 | 2016-06-16 | Synta Pharmaceuticals Corp. | Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer |
| US10208130B2 (en) | 2015-05-29 | 2019-02-19 | Expression Pathology, Inc. | Quantifying Her2 protein for optimal cancer therapy |
| CN107771076A (zh) * | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
| EP3534948A1 (en) * | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| CN110099926A (zh) * | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
| CR20190376A (es) * | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
| EP3589661B1 (en) * | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvant treatment of her2-positive breast cancer |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| CN114728101B (zh) * | 2019-06-28 | 2023-07-14 | 德州大学系统董事会 | 重构脂质体安那霉素的方法 |
| BR112021026506A2 (pt) | 2019-06-28 | 2022-02-15 | Univ Texas | Método para fabricar anamicina liofilizada, método para produzir liofilizado de anamicina pré-lipossômico, composição de liofilizado de anamicina pré-lipossômico e método para tratar câncer |
| WO2021222068A1 (en) * | 2020-04-29 | 2021-11-04 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment |
| CN111710425A (zh) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 |
| WO2023108012A1 (en) * | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL74201A0 (en) | 1984-01-30 | 1985-04-30 | Icrf Patents Limited | Polypeptides for the detection and control of mammalian cell growth |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| PT950067E (pt) | 1996-11-27 | 2007-12-06 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AU765003B2 (en) | 1998-03-27 | 2003-09-04 | Genentech Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| EP1187632B1 (en) | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| AU779209B2 (en) | 1999-06-25 | 2005-01-13 | Genentech Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| TR200200472T2 (tr) | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| SI1501856T1 (sl) | 2002-04-10 | 2013-04-30 | Genentech, Inc. | Variante protitelesa proti HER2 |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| PT2263691E (pt) | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
| EP3388452A3 (en) | 2002-09-11 | 2019-02-20 | Genentech, Inc. | Protein purification |
| AU2003277044A1 (en) * | 2002-09-30 | 2004-04-23 | The Trustees Of Boston University | Method of treating cancer using adenosine and its analogs |
| AU2003295798B2 (en) | 2002-11-21 | 2009-09-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
| SI3095793T1 (sl) | 2003-07-28 | 2020-07-31 | Genentech, Inc. | Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A |
| EP1737489B1 (en) | 2004-04-08 | 2012-01-11 | David B Agus | ErbB2 antagonists for tumor pain therapy |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| US20050280299A1 (en) | 2004-06-18 | 2005-12-22 | Alfmeier Corporation | Mounting adaptor for seat assembly, and seat assembly having mounting adaptor |
| KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008518902A (ja) * | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 |
| WO2006063042A2 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| KR20170134771A (ko) * | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| SI3248600T1 (sl) * | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| MY157955A (en) | 2005-07-06 | 2016-08-30 | Hoffmann La Roche | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| US20080038271A1 (en) * | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| US7816300B2 (en) | 2006-06-14 | 2010-10-19 | Cataler Corporation | Catalyst for purifying exhaust gas |
| SG174090A1 (en) | 2006-08-21 | 2011-09-29 | Hoffmann La Roche | Tumor therapy with an anti-vegf antibody |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
| KR101169243B1 (ko) | 2007-06-06 | 2012-08-02 | 에프. 호프만-라 로슈 아게 | 종양 항원에 결합하는 비-표지된 제 1 단클론 항체 및 ｎｉｒ 형광 표지로 표지된 비-교차 반응성 제 2 단클론 항체로 이루어진 조성물 |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| JP2011500684A (ja) * | 2007-10-19 | 2011-01-06 | バイパー サイエンシズ，インコーポレイティド | ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物 |
| DK2215117T4 (en) | 2007-10-30 | 2018-04-09 | Genentech Inc | ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090203015A1 (en) * | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| JP2011513432A (ja) | 2008-03-06 | 2011-04-28 | ジェネンテック， インコーポレイテッド | ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法 |
| HUE025507T2 (en) | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| SI2752189T1 (sl) * | 2008-11-22 | 2017-02-28 | F. Hoffmann-La Roche Ag | Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20110165155A1 (en) * | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| US20130095172A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
-
2012
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 KR KR1020237005562A patent/KR20230028585A/ko not_active Application Discontinuation
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/ko active IP Right Grant
- 2012-10-11 EA EA201490779A patent/EA034390B1/ru active Protection Beyond IP Right Term
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/zh active Pending
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 KR KR1020237015216A patent/KR20230073340A/ko active Application Filing
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 PL PL12778010T patent/PL2766040T3/pl unknown
- 2012-10-11 ES ES12778010T patent/ES2736005T3/es active Active
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/zh active Pending
- 2012-10-11 SI SI201231637T patent/SI2766040T1/sl unknown
- 2012-10-11 RS RS20190845A patent/RS58944B1/sr unknown
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/pt not_active Application Discontinuation
- 2012-10-11 EP EP23172847.8A patent/EP4241849A3/en active Pending
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/es active IP Right Grant
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en active Pending
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/zh active Active
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/zh active Pending
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/ko active IP Right Grant
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/es active IP Right Grant
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/zh active Active
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 UA UAA201709999A patent/UA123092C2/uk unknown
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/zh active Pending
- 2012-10-11 EP EP23172794.2A patent/EP4234033A3/en active Pending
- 2012-10-11 PT PT12778010T patent/PT2766040T/pt unknown
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/da active
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/ja not_active Withdrawn
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en active Application Filing
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/hu unknown
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/zh active Pending
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/zh active Pending
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/lt unknown
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-11-10 UA UAA201405091A patent/UA116095C2/uk unknown
-
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/es unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/es unknown
-
2015
- 2015-03-17 HK HK15102729.7A patent/HK1202242A1/xx unknown
-
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
-
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/ja not_active Withdrawn
-
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-07-11 HR HRP20191247TT patent/HRP20191247T1/hr unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/ja active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
-
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/ja not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
-
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
-
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/ja not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en active Pending
-
2023
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en active Pending
- 2023-04-28 US US18/309,452 patent/US20230277663A1/en active Pending
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/ja active Active
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/ja active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2766040T3 (pl) | Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi | |
| IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
| IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
| HK1254859A1 (zh) | 治療乳腺癌的方法 | |
| EP2744830A4 (en) | ANTI-LSR ANTIBODIES AND THEIR USES FOR THE TREATMENT OF CANCER | |
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| PL3254695T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu | |
| EP2755679A4 (en) | IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER |